ACM Global's Response to Coronavirus Disease 2019 (COVID-19)

As the novel coronavirus (COVID-19) continues to spread in the U.S. and across the globe, I want to take a moment to let you know what ACM Global Laboratories is doing to respond to this public health emergency.

First and foremost, ACM’s number one priority is the safety and well-being of our people, clients, families, and the communities in which we live and work.

We’ve assembled an executive level dedicated global COVID-19 Task Force (GCTF) to continually monitor the COVID-19 public health emergency and to put measures in place that help ensure both safety for our people and business continuity for our clients.

We are assessing the situation in real-time, remaining vigilant, and following all recommendations from the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC) and local authorities.

ACM continues to develop, update and share guidance with our professionals so they are fully informed on how to protect themselves, their families and their clients against transmission of the virus as this situation evolves.

Please be assured that while we remain focused on the health and safety of our professionals and those around us, we also are focused on continued service to our clients. We have taken steps to make sure we can continue to deliver the level of quality, excellence and timeliness you are accustomed to from us during these unique circumstances.

ACM has long been committed to a flexible work place, and we have the technological, cultural and operational infrastructure for the organization to work virtually, should the need arise. Additionally, we have put into place policies that require all guests at ACM offices and events to confirm that they do not pose a risk to others, based on certain criteria.

As we navigate this time of uncertainty together, I want to reaffirm ACM’s commitment to deliver actionable clinical insights that lead to therapies and treatments that provide health, healing and hope to patients around the world.

Sincerely,

Brian H. Wright

President, ACM Global Laboratories